m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05102
|
[1] | |||
Non-coding RNA
LncNAP1L6
HNRNPC
lncRNA miRNA circRNA
Direct
Enhancement
m6A modification
NAP1L2
NAP1L2
HNRNPC
 : m6A sites
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) | READER | |||
| m6A Target | Nucleosome assembly protein 1-like 2 (NAP1L2) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | Nucleosome assembly protein 1 like 6, pseudogene (NAP1L6P) | LncRNA | View Details | ||
| Regulated Target | Heterogeneous nuclear ribonucleoprotein C (HNRNPC) | View Details | |||
| Crosstalk Relationship | ncRNA → m6A | Enhancement | |||
| Crosstalk Mechanism | ncRNAs directly impacts m6A modification through recruiting m6A regulator | ||||
| Crosstalk Summary | NAP1L6P activates MMP pathway by stabilizing the m6A-modified Nucleosome assembly protein 1-like 2 (NAP1L2) to promote malignant progression in prostate cancer. lncNAP1L6 recruited HNRNPC to m6A-modified NAP1L2, leading to stabilization of NAP1L2 mRNA. | ||||
| Responsed Disease | Prostate cancer | ICD-11: 2C82 | |||
In-vitro Model |
22Rv1 | Prostate carcinoma | Homo sapiens | CVCL_1045 | |
| HNC PC3 | Retromolar trigone squamous cell carcinoma | Homo sapiens | CVCL_C8XA | ||
| LNCaP C4-2B | Prostate carcinoma | Homo sapiens | CVCL_4784 | ||
| VCaP | Prostate carcinoma | Homo sapiens | CVCL_2235 | ||
| DU145 | Prostate carcinoma | Homo sapiens | CVCL_0105 | ||
| RWPE-1 | Normal | Homo sapiens | CVCL_3791 | ||
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
| 2C82: Prostate cancer | 1 Compound(s) Regulating the Disease | Click to Show/Hide the Full List | ||
 Compound Name |
CC-94676 | Phase 1 | [2] | |
|---|---|---|---|---|
| External Link | ||||
References